# Hyperviscosity syndrome in Waldenström macroglobulinaemia and myeloma: recognition and plasma exchange

Source: https://onco.cc/protocols/hyperviscosity-syndrome-plasma-exchange/  
OnCo record `hyperviscosity-syndrome-plasma-exchange` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In Waldenström macroglobulinaemia, and less often in myeloma, an abnormal antibody protein can build up until the blood is too thick to flow through small vessels. Warning signs are nosebleeds or bleeding gums that will not stop, blurred or lost vision, headache, dizziness or drowsiness. It is an emergency: a machine removes and replaces the plasma (plasma exchange), then the cancer is treated.

## Summary

Hyperviscosity syndrome (HVS) is a clinical diagnosis (BSH 2022): mucosal bleeding, visual disturbance and neurological symptoms in someone with a high paraprotein. ASFA 2026 puts it in 10% to 30% of people with Waldenström macroglobulinaemia and 2% to 6% with myeloma (typically IgA or IgG3). In two retrospective cohorts it occurred in 14% of 825 and 13% of 997 patients with Waldenström macroglobulinaemia and did not change overall survival. Fundoscopy is part of the assessment: retinal changes can be present without visual symptoms and are themselves a reason to treat (Gertz 2018, Weaver 2020). Plasma exchange is not held for a viscosity result (Gertz 2018).

The guidelines read agree on plasma exchange for symptomatic HVS. ASFA puts it in category I (accepted first-line therapy) with grade 1B, a strong recommendation on moderate-quality evidence, and counts no randomised trial behind it (3 controlled trials and more than 10 case series). BSH gives Grade A1, calling hyperviscosity a haematological emergency and also an indication for definitive treatment. The Mayo mSMART guideline (2016) says exchange should be promptly initiated before cytoreductive therapy (level 3, grade B). ASFA: 1 to 1.5 total plasma volumes, daily or every other day, albumin or plasma replacement, generally 1 to 3 procedures, with viscosity and immunoglobulin monitored; IgG is less intravascular than IgM, so 4 to 5 exchanges may be needed, with fluid shifts after the procedure. Exchange does not treat the disease: ASFA says IgM returns to baseline about 3 to 5 weeks later, so systemic treatment follows.

The sources differ on three points. Viscosity threshold: ASFA says most patients are symptomatic at 6 to 7 cp and that HVS can occur above 4 cP; BSH says it should be considered above 3 mPas, citing a series in which about half of 85 symptomatic patients were below 4 mPas; Gertz says no level can be specified for exchange without symptoms. Rituximab IgM flare: ASFA (category I, grade 1C, from 3 case series and 3 case reports) says to consider exchange first when viscosity is above 3.5 cp or IgM above 4 g/dL (40 g/L), or else to hold rituximab for 1 to 3 cycles; BSH (Grade C1) says to defer rituximab or perform prophylactic plasmapheresis when IgM is above 40 g/L; mSMART (level 3, grade A) says rituximab alone is best avoided at a very high IgM without pre-emptive plasmapheresis, and names no figure; Gertz calls pre-emptive exchange unproven against close monitoring. Whether an IgM above 60 g/L alone should start treatment: one cohort says yes, another no (variants).

On red cell transfusion before viscosity is lowered, Weaver 2020 says to take caution to avoid excessive red cell or platelet transfusion, and Gertz 2018 says a theoretical argument could be made to withhold transfusion in haemodynamically stable patients while stating there is no scientific proof; neither ASFA nor BSH mentions it. The reader's own haematology team's protocol comes first; this page is for understanding the care, not for directing it.

## Fields

- Kind: Protocol
- Last checked: 2026-11-16
- Also known as: hyperviscosity syndrome; HVS; plasmapheresis for hyperviscosity; therapeutic plasma exchange for hyperviscosity; IgM flare; rituximab flare; thick blood from a paraprotein; paraprotein hyperviscosity

## Connected records

- protocols: [Hyperleukocytosis and leukostasis in acute leukaemia: supportive care, cytoreduction and leukapheresis](https://onco.cc/protocols/hyperleukocytosis-leukostasis/), [Red cell and platelet transfusion thresholds in cancer care](https://onco.cc/protocols/red-cell-and-platelet-transfusion-thresholds/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- drugs: [Rituximab](https://onco.cc/drugs/rituximab/)
- terms: [Apheresis (leukapheresis)](https://onco.cc/terms/apheresis/), [M-protein, immunofixation and serum free light chains](https://onco.cc/terms/m-protein-free-light-chains/)
- ideas: [Plasma exchange before rituximab compared with holding rituximab back, for a high IgM in Waldenström macroglobulinaemia](https://onco.cc/ideas/idea-upgrade-rituximab-igm-flare-prevention-comparison/)

---
JSON: https://onco.cc/api/v1/entities/hyperviscosity-syndrome-plasma-exchange.json